Jeffrey S Wagener
Overview
Explore the profile of Jeffrey S Wagener including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morgan W, VanDevanter D, Pasta D, Foreman A, Wagener J, Konstan M
J Pediatr
. 2023 Jan;
255:265.
PMID: 36653281
No abstract available.
2.
Konstan M, Pasta D, VanDevanter D, Wagener J, Morgan W
Pediatr Pulmonol
. 2021 Jan;
56(5):823-836.
PMID: 33434406
The Epidemiologic Study of Cystic Fibrosis (ESCF) was a prospective observational study of over 32,000 people with cystic fibrosis (CF) from 250 clinical care sites in North America from 1994...
3.
Wagener J, VanDevanter D, Konstan M, Pasta D, Millar S, Morgan W
Pediatr Pulmonol
. 2019 Nov;
55(3):828-834.
PMID: 31746561
Background: In cystic fibrosis, observation of a lung function drop (as percent predicted forced expiratory volume in 1 s [FEV ]; ppFEV ) frequently precedes pulmonary exacerbation (PEx) diagnosis. Recovery...
4.
Wagener J, Williams M, Millar S, Morgan W, Pasta D, Konstan M
J Cyst Fibros
. 2018 Apr;
17(4):496-502.
PMID: 29685810
Background: Patients with cystic fibrosis (CF) who experience acute declines in percent predicted FEV (ppFEV decreased ≥10% relative to baseline) are often not treated with antibiotics for pulmonary exacerbations (PEx),...
5.
Wagener J, Millar S, Mayer-Hamblett N, Sawicki G, McKone E, Goss C, et al.
J Cyst Fibros
. 2017 Nov;
17(4):503-510.
PMID: 29100868
Background: Patients with cystic fibrosis (CF) experience variable lung disease phenotypes. The R117H mutation is often associated with preserved lung function. Our objective was to compare the rate of lung...
6.
Konstan M, Wagener J, VanDevanter D, Pasta D, Millar S, Morgan W
Pediatr Pulmonol
. 2017 Jul;
52(8):1013-1019.
PMID: 28672067
Objectives: The Global Lung Function Initiative (GLI, 2012) developed reference equations for forced expiratory volume in 1 s (FEV ). Previous equations were developed by groups led by Knudson (1983),...
7.
Flume P, Wainwright C, Tullis D, Rodriguez S, Niknian M, Higgins M, et al.
J Cyst Fibros
. 2017 Jun;
17(1):83-88.
PMID: 28651844
Background: Pulmonary exacerbations (PEx) are associated with acute loss of lung function that is often not recovered after treatment. We investigated lung function recovery following PEx for ivacaftor- and placebo-treated...
8.
Sawicki G, McKone E, Millar S, Pasta D, Konstan M, Lubarsky B, et al.
Am J Respir Crit Care Med
. 2017 Jun;
195(12):1673-1676.
PMID: 28617084
No abstract available.
9.
Gardner A, Gray A, Self S, Wagener J
Patient Prefer Adherence
. 2017 Apr;
11:761-767.
PMID: 28435234
Background: Treatment regimens for patients with cystic fibrosis (CF) are complex, time consuming, and burdensome, and adherence to CF treatment is suboptimal. CF care teams play a critical role in...
10.
Morgan W, Wagener J, Pasta D, Millar S, VanDevanter D, Konstan M
Ann Am Thorac Soc
. 2017 Mar;
14(6):937-942.
PMID: 28324670
Rationale: Children with cystic fibrosis often experience acute declines in lung function. We previously showed that such declines are not always treated with antibiotics, but we did not assess whether...